A Polymorphism in the Complement Component C1qA Correlates With Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-08-0745
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

A Retrospective Study on the Management of Patients With Rituximab Refractory Follicular Lymphoma

British Journal of Haematology
Hematology
2017English

Characteristics and Outcomes of Patients With Relapsed Follicular Lymphoma Following Retreatment With Second-Line Rituximab-Containing Chemotherapy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Maintenance Rituximab or Observation After Frontline Treatment With Bendamustine-Rituximab for Follicular Lymphoma

British Journal of Haematology
Hematology
2018English

M7‐FLIPI Is Not Prognostic in Follicular Lymphoma Patients With First‐line Rituximab Chemo‐free Therapy

British Journal of Haematology
Hematology
2019English

Anti-Tumor Activity of Obinutuzumab and Rituximab in a Follicular Lymphoma 3D Model

Blood Cancer Journal
OncologyHematology
2013English

Real World Data on Rituximab Maintenance Therapy After Frontline Immunochemotherapy in Grade 1-3a Follicular Lymphoma

British Journal of Haematology
Hematology
2017English

Rituximab-Induced Acute Thrombocytopenia in a Patient With Follicular Lymphoma: A Case Report and Review of the Literature

Internal Medicine
Internal MedicineMedicine
2018English

Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2010English

Consolidation Therapy for Follicular Lymphoma

European Oncology and Haematology
OncologyHematology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy